PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35212616-4 2022 Lidocaine suppressed A431 cell proliferation and cisplatin resistance in a dose- and time-dependent manner via the miR-30c/SIRT1 pathway. Cisplatin 49-58 sirtuin 1 Homo sapiens 123-128 35403781-5 2022 Gene expression of HDAC1, HDAC2, SIRT1, MTA1, KAT2B, KAT6A, KAT6B, and BRD4 indicated the cisplatin activates the epigenetic machinery. Cisplatin 90-99 sirtuin 1 Homo sapiens 33-38 32881246-2 2020 Apoptosis is associated with mitochondrial dysfunction and SIRT1 activation can decrease cell apoptosis in cisplatin nephrotoxicity. Cisplatin 107-116 sirtuin 1 Homo sapiens 59-64 32881246-10 2020 These results implied PIO attenuated cisplatin nephrotoxicity by suppressing mitochondria-mediated apoptosis through regulating SIRT1/p53 signalling. Cisplatin 37-46 sirtuin 1 Homo sapiens 128-133 32210821-0 2020 SIRT1 Mediates Effects of FGF21 to Ameliorate Cisplatin-Induced Acute Kidney Injury. Cisplatin 46-55 sirtuin 1 Homo sapiens 0-5 32884297-0 2020 MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway. Cisplatin 21-30 sirtuin 1 Homo sapiens 88-93 32884297-0 2020 MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway. Cisplatin 56-65 sirtuin 1 Homo sapiens 88-93 32884297-12 2020 Furthermore, overexpression of SIRT1 was responsible for the resistance to cisplatin in PC9/R and A549/R cells. Cisplatin 75-84 sirtuin 1 Homo sapiens 31-36 32884297-15 2020 Conclusion: MiR-140 resensitizes cisplatin-resistant NSCLC cells to cisplatin treatment through the SIRT1/ROS/JNK pathway. Cisplatin 33-42 sirtuin 1 Homo sapiens 100-105 32884297-15 2020 Conclusion: MiR-140 resensitizes cisplatin-resistant NSCLC cells to cisplatin treatment through the SIRT1/ROS/JNK pathway. Cisplatin 68-77 sirtuin 1 Homo sapiens 100-105 32489467-0 2020 Cytoplasm-localized SIRT1 downregulation attenuates apoptosis and cell cycle arrest in cisplatin-resistant lung cancer A549 cells. Cisplatin 87-96 sirtuin 1 Homo sapiens 20-25 32489467-1 2020 Objective: We propose that sirtuin (SIRT) may induce a pro-apoptotic effect by deacetylating transcription factors in A549 cells: depletion of sirtuin-1 (SIRT1) induced cell cycle arrest in cisplatin-resistant A549 (A549/CADD) cells. Cisplatin 190-199 sirtuin 1 Homo sapiens 143-152 32489467-1 2020 Objective: We propose that sirtuin (SIRT) may induce a pro-apoptotic effect by deacetylating transcription factors in A549 cells: depletion of sirtuin-1 (SIRT1) induced cell cycle arrest in cisplatin-resistant A549 (A549/CADD) cells. Cisplatin 190-199 sirtuin 1 Homo sapiens 154-159 32489467-9 2020 We observed that cisplatin regulates p53 stability through the depletion of ubiquitination following SIRT1 downregulation. Cisplatin 17-26 sirtuin 1 Homo sapiens 101-106 32489467-10 2020 Furthermore, cisplatin treatment increased proteasomal activity and significantly decreased cytoplasmic SIRT1 protein levels in A549/CADD cells. Cisplatin 13-22 sirtuin 1 Homo sapiens 104-109 32349783-0 2020 Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1. Cisplatin 49-58 sirtuin 1 Homo sapiens 143-148 32052927-0 2020 LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling. Cisplatin 77-86 sirtuin 1 Homo sapiens 105-110 32210821-10 2020 Furthermore, administration of recombinant FGF21 to cisplatin-treated AKI models significantly increased SIRT1 expression, and the beneficial effects of FGF21 on kidney injury were reversed by SIRT1 knockdown. Cisplatin 52-61 sirtuin 1 Homo sapiens 105-110 32210821-10 2020 Furthermore, administration of recombinant FGF21 to cisplatin-treated AKI models significantly increased SIRT1 expression, and the beneficial effects of FGF21 on kidney injury were reversed by SIRT1 knockdown. Cisplatin 52-61 sirtuin 1 Homo sapiens 193-198 32210821-11 2020 Collectively, our results suggest that SIRT1 mediates the protective effect of FGF21 on cisplatin-induced kidney injury. Cisplatin 88-97 sirtuin 1 Homo sapiens 39-44 30692914-8 2018 Notably, we found that CDDP-induced increase of Sirtuin 1 (SIRT1) in the HEI-OC1 cells modulated the autophagy function. Cisplatin 23-27 sirtuin 1 Homo sapiens 48-57 31400413-0 2019 Porous Se@SiO2 nanospheres attenuate cisplatin-induced acute kidney injury via activation of Sirt1. Cisplatin 37-46 sirtuin 1 Homo sapiens 93-98 31400413-8 2019 In terms of mechanism, we discovered that Sirt1, a deacetylase with an important role in CDDP-induced acute kidney injury, was remarkedly increased after NPs pretreatment, and the anti-apoptotic effect of the NPs was markedly abrogated after the inhibition of Sirt1. Cisplatin 89-93 sirtuin 1 Homo sapiens 42-47 31056532-0 2019 MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway. Cisplatin 19-28 sirtuin 1 Homo sapiens 109-114 31056532-9 2019 We then demonstrated that overexpression of miR-124 sensitized cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway. Cisplatin 63-72 sirtuin 1 Homo sapiens 153-158 30692914-8 2018 Notably, we found that CDDP-induced increase of Sirtuin 1 (SIRT1) in the HEI-OC1 cells modulated the autophagy function. Cisplatin 23-27 sirtuin 1 Homo sapiens 59-64 30692914-9 2018 The specific SIRT1 activator SRT1720 could successfully protect against CDDP-induced cell loss in HEI-OC1 cells, zebrafish lateral line, and mice cochlea. Cisplatin 72-76 sirtuin 1 Homo sapiens 13-18 30447351-0 2019 N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation. Cisplatin 29-38 sirtuin 1 Homo sapiens 104-112 30058691-0 2018 Expression of SIRT1 gene in human lung cancer lines enhances their sensitivity to the anticancer effects of cisplatin. Cisplatin 108-117 sirtuin 1 Homo sapiens 14-19 30008835-0 2018 MicroRNA-29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression. Cisplatin 22-31 sirtuin 1 Homo sapiens 89-98 30058691-11 2018 The three differentially SIRT1 expressing cancer cell lines were subjected to cisplatin treatment. Cisplatin 78-87 sirtuin 1 Homo sapiens 25-30 30058691-14 2018 CONCLUSIONS: Expression of SIRT1 gene determines the sensitivity of lung cancer cells to anticancer effects of cisplatin. Cisplatin 111-120 sirtuin 1 Homo sapiens 27-32 29382429-0 2017 [Knockdown of SIRT1 enhances the sensitivity to cisplatin by inhibiting autophagy in A549 cells]. Cisplatin 48-57 sirtuin 1 Homo sapiens 14-19 29382429-1 2017 Objective To inhibit cisplatin-induced autophagy and improve the cisplatin sensitivity of A549 cells by knockdown the silent information regulator of transcription 1 (SIRT1). Cisplatin 21-30 sirtuin 1 Homo sapiens 118-165 29382429-1 2017 Objective To inhibit cisplatin-induced autophagy and improve the cisplatin sensitivity of A549 cells by knockdown the silent information regulator of transcription 1 (SIRT1). Cisplatin 21-30 sirtuin 1 Homo sapiens 167-172 29382429-1 2017 Objective To inhibit cisplatin-induced autophagy and improve the cisplatin sensitivity of A549 cells by knockdown the silent information regulator of transcription 1 (SIRT1). Cisplatin 65-74 sirtuin 1 Homo sapiens 118-165 29382429-1 2017 Objective To inhibit cisplatin-induced autophagy and improve the cisplatin sensitivity of A549 cells by knockdown the silent information regulator of transcription 1 (SIRT1). Cisplatin 65-74 sirtuin 1 Homo sapiens 167-172 29382429-3 2017 After cisplatin treatment, the protein levels of SIRT1, LC3, P62 and beclin-1 in A549 cells were detected by Western blotting. Cisplatin 6-15 sirtuin 1 Homo sapiens 49-54 29382429-9 2017 After cisplatin treatment, the protein levels of SIRT1, LC3 and beclin-1 in A549 cells increased, while P62 decreased. Cisplatin 6-15 sirtuin 1 Homo sapiens 49-54 29382429-11 2017 Compared with cisplatin group, the number of the apoptotic cells increased with the obvious occurrence of pyknosis and nuclear fragmentation in cisplatin plus SIRT1-siRNA group. Cisplatin 14-23 sirtuin 1 Homo sapiens 159-164 29382429-14 2017 The sensitivity of A549 cells to cisplatin can be improved by inhibiting the cisplatin-induced autophagy through knockdown of SIRT1. Cisplatin 33-42 sirtuin 1 Homo sapiens 126-131 29382429-14 2017 The sensitivity of A549 cells to cisplatin can be improved by inhibiting the cisplatin-induced autophagy through knockdown of SIRT1. Cisplatin 77-86 sirtuin 1 Homo sapiens 126-131 26341473-5 2016 Here, we demonstrate that the levels and activities of sirtuin-1 (SIRT1) are suppressed by the reduction of intracellular NAD(+) levels in cisplatin-mediated ototoxicity. Cisplatin 139-148 sirtuin 1 Homo sapiens 55-64 28567015-4 2017 USP22 and its downstream proteins gammaH2AX and Sirt1 levels are upregulated in the cisplatin- resistant A549/CDDP cell line. Cisplatin 84-93 sirtuin 1 Homo sapiens 48-53 28383763-0 2017 Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Cisplatin 80-89 sirtuin 1 Homo sapiens 105-110 28383763-15 2017 Thus, we concluded that miR-132 regulated SIRT1/CREB/ABCG2 signaling pathway contributing to the cisplatin resistance and might serve as a novel therapeutic target against gastric cancer. Cisplatin 97-106 sirtuin 1 Homo sapiens 42-47 27186285-0 2016 Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. Cisplatin 39-48 sirtuin 1 Homo sapiens 20-25 27186285-1 2016 There is accumulating evidence that breast cancer 1 (BRCA1), sirtuin 1 (SIRT1), and epidermal growth factor receptor (EGFR) help to modulate cisplatin cytotoxicity. Cisplatin 141-150 sirtuin 1 Homo sapiens 61-70 27186285-1 2016 There is accumulating evidence that breast cancer 1 (BRCA1), sirtuin 1 (SIRT1), and epidermal growth factor receptor (EGFR) help to modulate cisplatin cytotoxicity. Cisplatin 141-150 sirtuin 1 Homo sapiens 72-77 27186285-3 2016 We found that BRCA1, SIRT1, and EGFR levels were increased in cisplatin-resistant ovarian cancers compared with those in cisplatin-sensitive ovarian cancers. Cisplatin 62-71 sirtuin 1 Homo sapiens 21-26 27186285-5 2016 Treatment with 5 and 10 mug/ml cisplatin induced a gradual increase in BRCA1 and SIRT1 levels and a gradual decrease in NAD levels and NAD-mediated SIRT1 activity, whereas EGFR levels were increased or decreased by treatment with 5 or 10 mug/ml cisplatin, respectively. Cisplatin 31-40 sirtuin 1 Homo sapiens 81-86 27186285-5 2016 Treatment with 5 and 10 mug/ml cisplatin induced a gradual increase in BRCA1 and SIRT1 levels and a gradual decrease in NAD levels and NAD-mediated SIRT1 activity, whereas EGFR levels were increased or decreased by treatment with 5 or 10 mug/ml cisplatin, respectively. Cisplatin 31-40 sirtuin 1 Homo sapiens 148-153 26341473-5 2016 Here, we demonstrate that the levels and activities of sirtuin-1 (SIRT1) are suppressed by the reduction of intracellular NAD(+) levels in cisplatin-mediated ototoxicity. Cisplatin 139-148 sirtuin 1 Homo sapiens 66-71 26341473-6 2016 We provide evidence that the decreases in SIRT1 activity and expression facilitated by increasing poly(ADP-ribose) polymerase-1 (PARP-1) activation and microRNA-34a levels through cisplatin-mediated p53 activation aggravate the associated ototoxicity. Cisplatin 180-189 sirtuin 1 Homo sapiens 42-47 26341473-7 2016 Furthermore, we show that the induction of cellular NAD(+) levels using dunnione, which targets intracellular NQO1, prevents the toxic effects of cisplatin through the regulation of PARP-1 and SIRT1 activity. Cisplatin 146-155 sirtuin 1 Homo sapiens 193-198 25973238-0 2015 Higher expression of SIRT1 induced resistance of esophageal squamous cell carcinoma cells to cisplatin. Cisplatin 93-102 sirtuin 1 Homo sapiens 21-26 26903157-0 2016 [SIRT1 Influences the Sensitivity of A549 Non-small Cell Lung Cancer Cell Line to : Cisplatin via Modulating the Noxa Expression]. Cisplatin 85-94 sirtuin 1 Homo sapiens 1-6 26498527-4 2015 In the present study, we demonstrated that the hyper-activation of poly(ADP-ribose) polymerase-1 (PARP-1) is closely associated with the depletion of NAD(+) in the small intestine after cisplatin treatment, which results in downregulation of sirtuin1 (SIRT1) activity. Cisplatin 186-195 sirtuin 1 Homo sapiens 242-250 26498527-4 2015 In the present study, we demonstrated that the hyper-activation of poly(ADP-ribose) polymerase-1 (PARP-1) is closely associated with the depletion of NAD(+) in the small intestine after cisplatin treatment, which results in downregulation of sirtuin1 (SIRT1) activity. Cisplatin 186-195 sirtuin 1 Homo sapiens 252-257 26498527-5 2015 Furthermore, a decrease in SIRT1 activity was found to play an important role in cisplatin-mediated small intestinal damage through nuclear factor (NF)-kappaB p65 activation, facilitated by its acetylation increase. Cisplatin 81-90 sirtuin 1 Homo sapiens 27-32 26498527-6 2015 However, use of dunnione as a strong substrate for the NADH:quinone oxidoreductase 1 (NQO1) enzyme led to an increase in intracellular NAD(+) levels and prevented the cisplatin-induced small intestinal damage correlating with the modulation of PARP-1, SIRT1, and NF-kappaB. Cisplatin 167-176 sirtuin 1 Homo sapiens 252-257 26367491-0 2015 Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target. Cisplatin 34-43 sirtuin 1 Homo sapiens 0-9 26367491-8 2015 SIRT1 overexpression significantly enhanced the resistance for cisplatin and paclitaxel in HHUA cells. Cisplatin 63-72 sirtuin 1 Homo sapiens 0-5 26367491-9 2015 Although p53 is an important target protein for SIRT1, the selective SIRT1 inhibitor (EX527) significantly suppressed the proliferation and cisplatin resistance of three endometrial carcinoma cell lines regardless of the p53 mutation status. Cisplatin 140-149 sirtuin 1 Homo sapiens 69-74 26367491-10 2015 In addition, SIRT1 overexpression in HHUA cells accelerated tumor growth and cisplatin resistance in nude mice, and EX527 significantly suppressed the growth of tumors of HHUA and HEC1B cells. Cisplatin 77-86 sirtuin 1 Homo sapiens 13-18 26048190-6 2015 In addition, its differential expression was linked to Sirt1-induced cisplatin resistance of oral squamous cell carcinoma (OSCC) and miR-7-induced migration and invasion inhibition of glioma. Cisplatin 69-78 sirtuin 1 Homo sapiens 55-60 25973238-3 2015 This study was designed to explore the relationship between SIRT1 expression and resistance of esophageal squamous cell carcinoma (ESCC) cells to cisplatin and reveal the underlying mechanism. Cisplatin 146-155 sirtuin 1 Homo sapiens 60-65 25973238-10 2015 The influence of SIRT1 silence on sensitivity of ECa9706-CisR cells to cisplatin was confirmed using CCK-8 assay and flow cytometry. Cisplatin 71-80 sirtuin 1 Homo sapiens 17-22 25973238-14 2015 Cisplatin 5 microM could cause proliferation inhibition, G2/M phase arrest and apoptosis in ECa9706-CisR cells and these effects could be enhanced dramatically by SIRT1 silencing. Cisplatin 0-9 sirtuin 1 Homo sapiens 163-168 25973238-16 2015 CONCLUSIONS: Over-expression of SIRT1 may cause resistance of ESCC cells to cisplatin through the mechanism involved with Noxa expression. Cisplatin 76-85 sirtuin 1 Homo sapiens 32-37 24922076-7 2014 Moreover, we show that the induction of cellular NAD(+) levels using beta-lapachone (beta-Lap), whose intracellular target is NQO1, prevents the toxic effects of cisplatin through the regulation of PARP-1 and SIRT1 activity. Cisplatin 162-171 sirtuin 1 Homo sapiens 209-214 24922076-5 2014 Here, we demonstrate for the first time that, in cisplatin-mediated ototoxicity, the levels and activities of SIRT1 are suppressed by the reduction of intracellular NAD(+) levels. Cisplatin 49-58 sirtuin 1 Homo sapiens 110-115 24922076-6 2014 We provide evidence that the decrease in SIRT1 activity and expression facilitated by increasing poly(ADP-ribose) transferase (PARP)-1 activation and microRNA-34a through p53 activation aggravates cisplatin-mediated ototoxicity. Cisplatin 197-206 sirtuin 1 Homo sapiens 41-46 24223900-14 2013 More importantly, SIRT1 si-RNA significantly enhanced the chemosensitivity of H292 cells to cisplatin treatment. Cisplatin 92-101 sirtuin 1 Homo sapiens 18-23 23542177-5 2014 Moreover, knockdown of SIRT1 blocks the cisplatin (CDDP)-induced nuclear translocation of YAP2 and enhances the chemosensitivity of HCC cells to CDDP treatment. Cisplatin 40-49 sirtuin 1 Homo sapiens 23-28 23542177-5 2014 Moreover, knockdown of SIRT1 blocks the cisplatin (CDDP)-induced nuclear translocation of YAP2 and enhances the chemosensitivity of HCC cells to CDDP treatment. Cisplatin 51-55 sirtuin 1 Homo sapiens 23-28 23542177-5 2014 Moreover, knockdown of SIRT1 blocks the cisplatin (CDDP)-induced nuclear translocation of YAP2 and enhances the chemosensitivity of HCC cells to CDDP treatment. Cisplatin 145-149 sirtuin 1 Homo sapiens 23-28 24240701-0 2014 SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. Cisplatin 84-93 sirtuin 1 Homo sapiens 0-5 24240701-6 2014 Notably, hypoxic inactivation of this SIRT1-AMPK pathway led to cisplatin and doxorubicin resistance. Cisplatin 64-73 sirtuin 1 Homo sapiens 38-43 24240701-9 2014 Furthermore, we demonstrated that a SIRT1 activator SRT1720 augmented the antitumor effects of cisplatin, and these effects could be blocked by administration of an AMPK inhibitor compound C. Taken together, our results offer preclinical proof-of-concept to target the SIRT1-AMPK pathway as a strategy to overcome hypoxia-induced chemoresistance in NSCLC. Cisplatin 95-104 sirtuin 1 Homo sapiens 36-41 24240701-9 2014 Furthermore, we demonstrated that a SIRT1 activator SRT1720 augmented the antitumor effects of cisplatin, and these effects could be blocked by administration of an AMPK inhibitor compound C. Taken together, our results offer preclinical proof-of-concept to target the SIRT1-AMPK pathway as a strategy to overcome hypoxia-induced chemoresistance in NSCLC. Cisplatin 95-104 sirtuin 1 Homo sapiens 269-274 34590923-8 2021 In addition, SIRT1 overexpression diminished the effects of puerarin treatment on cisplatin-resistant ovarian cancer cells. Cisplatin 82-91 sirtuin 1 Homo sapiens 13-18 22330808-0 2012 SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kappaB p65 subunit and cytotoxicity in renal proximal tubule cells. Cisplatin 31-40 sirtuin 1 Homo sapiens 0-5 22330808-5 2012 To investigate the effect of SIRT1 in on cisplatin-induced acetylation of p65 subunit of NF-kappaB and cell injury, HK2 cells were exposed with SIRT1 overexpression, LacZ adenovirus or dominant negative adenovirus after treatment with cisplatin. Cisplatin 41-50 sirtuin 1 Homo sapiens 29-34 22330808-6 2012 While protein expression of SIRT1 was decreased by cisplatin treatment compared with control buffer treatment, acetylation of NF-kappaB p65 subunit was significantly increased after treatment with cisplatin. Cisplatin 51-60 sirtuin 1 Homo sapiens 28-33 22330808-7 2012 Overexpression of SIRT1 ameliorated the increased acetylation of p65 of NF-kappaB during cisplatin treatment and cisplatin-induced cytotoxicity. Cisplatin 89-98 sirtuin 1 Homo sapiens 18-23 22330808-7 2012 Overexpression of SIRT1 ameliorated the increased acetylation of p65 of NF-kappaB during cisplatin treatment and cisplatin-induced cytotoxicity. Cisplatin 113-122 sirtuin 1 Homo sapiens 18-23 22330808-8 2012 Further, treatment of cisplatin-treated HK2 cells with resveratrol, a SIRT1 activator, also decreased acetylation of NF-kappaB p65 subunit and cisplatin-induced increase of the cell viability in HK2 cells. Cisplatin 22-31 sirtuin 1 Homo sapiens 70-75 22330808-8 2012 Further, treatment of cisplatin-treated HK2 cells with resveratrol, a SIRT1 activator, also decreased acetylation of NF-kappaB p65 subunit and cisplatin-induced increase of the cell viability in HK2 cells. Cisplatin 143-152 sirtuin 1 Homo sapiens 70-75 22330808-9 2012 Our findings suggests that the regulation of acetylation of p65 of NF-kappaB through SIRT1 can be a possible target to attenuate cisplatin-induced renal cell damage. Cisplatin 129-138 sirtuin 1 Homo sapiens 85-90 21947960-0 2011 Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line. Cisplatin 37-46 sirtuin 1 Homo sapiens 22-27 21947960-3 2011 Sirt1, a class III histone deacetylase, was linked to cisplatin resistance in several cancer types; however, the underlying mechanism is still unclear. Cisplatin 54-63 sirtuin 1 Homo sapiens 0-5 21947960-4 2011 Here, we demonstrated that overexpression of Sirt1 survived OSCC cell line Tca8113 under cisplatin treatment. Cisplatin 89-98 sirtuin 1 Homo sapiens 45-50 21947960-5 2011 Notably, BML-210, a chemical inhibitor of class III histone deacetylase, significantly abolished Sirt1-mediated cisplatin resistance in Tca8113 cells. Cisplatin 112-121 sirtuin 1 Homo sapiens 97-102 21947960-6 2011 Further, inactivation of endogenic Sirt1 by nicotinamide markedly increased chemo-sensitivity in cisplatin resistant sub-cell line Tca8113/CDDP. Cisplatin 97-106 sirtuin 1 Homo sapiens 35-40 21947960-6 2011 Further, inactivation of endogenic Sirt1 by nicotinamide markedly increased chemo-sensitivity in cisplatin resistant sub-cell line Tca8113/CDDP. Cisplatin 139-143 sirtuin 1 Homo sapiens 35-40 21947960-10 2011 Finally, we showed that Sirt1 could prevent cisplatin-induced ROS accumulation in Tca8113 cells. Cisplatin 44-53 sirtuin 1 Homo sapiens 24-29 21947960-11 2011 Our findings are considered as a significant step toward a better understanding of Sirt1-mediated cisplatin resistance. Cisplatin 98-107 sirtuin 1 Homo sapiens 83-88 21416250-0 2011 Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney. Cisplatin 0-9 sirtuin 1 Homo sapiens 18-23 21416250-3 2011 RESULTS: Administration of CDDP (5 mg/kg body weight) caused an increase in the Sirt1 protein level by 6 h; this increase peaked at day 5 and declined until day 14. Cisplatin 27-31 sirtuin 1 Homo sapiens 80-85 21416250-9 2011 Transfection of Sirt1 to human embryonic kidney 293 cells mitigated the CDDP-induced cellular damage. Cisplatin 72-76 sirtuin 1 Homo sapiens 16-21 21416250-10 2011 CONCLUSIONS: These findings collectively suggest that CDDP increases the level of Sirt1 protein in the kidneys in association with histone H3 deacetylation and increased WRN and PCNA production. Cisplatin 54-58 sirtuin 1 Homo sapiens 82-87 21416250-11 2011 The induced Sirt1 may work defensively to mitigate CDDP-induced tubular damage by inactivating core histone transcriptionally, and by repairing DNA damage. Cisplatin 51-55 sirtuin 1 Homo sapiens 12-17 18723829-0 2008 SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Cisplatin 29-38 sirtuin 1 Homo sapiens 0-5 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 122-131 sirtuin 1 Homo sapiens 8-13 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 122-131 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 122-131 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 122-131 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 8-13 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 8-13 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 30-35 18723829-6 2008 Reduced SIRT1 expression by a SIRT1 SMART small interfering RNA duplex sensitized the >20-fold resistant CP-r cells to cisplatin treatment 1.5- to 2-fold, and SIRT1 overexpression by SIRT1 cDNA transfection increased cisplatin resistance in cisplatin-sensitive cells by 2- to 3-fold. Cisplatin 220-229 sirtuin 1 Homo sapiens 30-35 18723829-7 2008 Our findings therefore suggest that reduced glucose use and altered mitochondrial metabolism mediated by SIRT1 is one of several alterations that contribute to cellular resistance to cisplatin. Cisplatin 183-192 sirtuin 1 Homo sapiens 105-110 18573234-4 2008 Treatment with a SIRT1 inhibitor, sirtinol, inhibited cell growth and increased sensitivity to camptothecin and cisplatin. Cisplatin 112-121 sirtuin 1 Homo sapiens 17-22 34339961-0 2021 miR-132-3p promotes the cisplatin-induced apoptosis and inflammatory response of renal tubular epithelial cells by targeting SIRT1 via the NF-kappaB pathway. Cisplatin 24-33 sirtuin 1 Homo sapiens 125-130 34339961-13 2021 Mechanistically, the SIRT1 expression was suppressed and the NF-kappaB signaling pathway was activated by the upregulation of miR-132-3p in cisplatin-induced AKI. Cisplatin 140-149 sirtuin 1 Homo sapiens 21-26 34339961-16 2021 Our results suggested that miR-132-3p exacerbated cisplatin-induced AKI by negatively regulating SIRT1 and activating the NF-kappaB signaling pathway. Cisplatin 50-59 sirtuin 1 Homo sapiens 97-102 34184746-9 2021 Finally, inhibition or knockdown of Sirt1 suppressed USP31 activity in HeLa cell line, leading to cisplatin-induced apoptosis resistance. Cisplatin 98-107 sirtuin 1 Homo sapiens 36-41 35626727-7 2022 iTRAQ proteomics showed that SIRT1/Nrf2 signaling and MT1 proteins were downregulated in cisplatin-treated mouse testes. Cisplatin 89-98 sirtuin 1 Homo sapiens 29-34 35447421-12 2022 With various inhibitors and siRNAs, beta-lap reduced CDDP-induced damage to normal fibroblasts by maintaining mitochondrial activity and increasing autophagy through the NQO1/NAD+/SIRT1 axis. Cisplatin 53-57 sirtuin 1 Homo sapiens 180-185